The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1696
February 19, 2024
View Complete Issue         Table of Contents 2019 
Rozanolixizumab (Rystiggo) for Myasthenia Gravis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rozanolixizumab (Rystiggo) for Myasthenia Gravis
February 19, 2024 (Issue: 1696)
Rozanolixizumab-noli (Rystiggo – UCB), a neonatal Fc receptor (FcRn) blocker, has been approved by the FDA for treatment of generalized myasthenia gravis in adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Rozanolixizumab (Rystiggo) for Myasthenia Gravis
Article code: 1696c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.